

1
2
3
4
5 **UNITED STATES DISTRICT COURT**
6 **SOUTHERN DISTRICT OF CALIFORNIA**

7 JOHN SANDOVAL, on behalf
8 of himself and all others similarly
9 situated,

10
11 Plaintiff,

12 v.

13
14 PHARMACARE US, INC.,

15
16
17 Defendant.

CASE NO. 15-cv-0738-H-JLB

ORDER:

**(1) DENYING PLAINTIFF'S
MOTION FOR LEAVE TO
FILE A RENEWED MOTION
FOR CLASS CERTIFICATION
AND DENYING RENEWED
MOTION FOR CLASS
CERTIFICATION**

[Doc. Nos. 58, 59]

**(2) GRANTING DEFENDANT'S
MOTION FOR SUMMARY
JUDGMENT**

[Doc. No. 63]

**(3) DENYING DEFENDANT'S
MOTION FOR SANCTIONS**

[Doc. No. 71]

**(4) LIMITING THE USE OF
PLAINTIFF'S REBUTTAL
EXPERTS TO REBUTTAL**

[Doc. No. 71]

**(5) DENYING DEFENDANT'S
MOTION TO STRIKE AS MOOT**

[Doc. No. 67]

**(6) DENYING AS MOOT
PLAINTIFF'S MOTION
TO EXCLUDE THE REPORT
OF DEFENDANT'S EXPERT**

[Doc. No. 62]

1 This order addresses six motions: Plaintiff's motion for leave to file a renewed
 2 motion for class certification (Doc. No. 58), Plaintiff's renewed motion for class
 3 certification (Doc. No. 59), Plaintiff's motion to exclude the report of Defendant's
 4 expert (Doc. No. 62), Defendant's motion for summary judgment (Doc. No. 63),
 5 Defendant's motion to strike Plaintiff's renewed motion for class certification (Doc. No.
 6 67), and Defendant's motion to exclude Plaintiff's rebuttal experts and for sanctions
 7 (Doc. No. 71).

8 For the reasons set forth below, the Court denies Plaintiff's motions regarding
 9 class certification and grants Defendant's motion for summary judgment as to all claims
 10 other than the Magnuson-Moss Warranty Act claim, which the Court dismisses for lack
 11 of jurisdiction. Additionally, the Court denies Defendant's motion for sanctions but
 12 limits Plaintiff's use of his rebuttal experts to rebuttal. The Court denies as moot
 13 Defendant's motion to strike and denies as moot Plaintiff's motion to exclude the report
 14 of Defendant's expert.

15 BACKGROUND

16 Plaintiff John Sandoval filed this case on April 3, 2016. (Doc. No. 1.) He filed
 17 the operative first amended complaint on July 11, 2015. (Doc. No. 9, "FAC.") Plaintiff
 18 alleges that the labeling on Defendant's product IntenseX violates federal
 19 and California law because IntenseX is an unapproved aphrodisiac drug and the label
 20 claims are false or misleading. (*Id.*) He alleges that he bought IntenseX because he
 21 sought a product that would enhance his sexual power and performance, but he did
 22 not experience those benefits and IntenseX is incapable of providing those benefits.
 23 (*Id.* ¶¶ 76–79.)

24 Plaintiff alleges violations of California's Unfair Competition Law ("UCL"),
 25 Cal. Bus. & Prof. Code § 17200 et seq.; False Advertising Law ("FAL"), Cal. Bus.
 26 & Prof. Code § 17500 et seq.; Consumer Legal Remedies Act ("CLRA"), Cal. Civ.
 27 Code § 1770 et seq.; breach of express warranty; breach of the implied warranty
 28 of merchantability; and violation of the federal Magnuson-Moss Warranty Act.

1 (FAC ¶¶ 99–146.) Plaintiff alleges jurisdiction under the Class Action Fairness Act,
2 28 U.S.C. § 1332(d)(2). (FAC ¶ 1.)

3 On September 30, 2015, the Court denied Defendant’s motion to dismiss
4 and strike portions of Plaintiff’s first amended complaint. (Doc. No. 17.) The Court
5 concluded that the Food, Drug, and Cosmetic Act preempted Plaintiff’s theory that the
6 IntenseX label made impermissible disease claims but did not preempt Plaintiff’s other
7 theories. (Id. at 6–10.) The Court determined that many of the remaining claims were
8 better suited for resolution at summary judgment. (Id. at 19.)

9 Defendant answered on October 14, 2015. (Doc. No. 21.) Following a case
10 management conference, on December 2, 2015, the Court entered a scheduling order
11 regulating discovery and pretrial proceedings. (Doc. No. 26.) On January 15, 2016, the
12 Court entered an amended scheduling order. (Doc. No. 27.)

13 The amended scheduling order specified that all discovery, including expert
14 discovery, must be complete by July 29, 2016. (Id. ¶ 2.) The order directed the parties
15 to disclose their experts by May 27, 2016, and their rebuttal experts by June 29, 2016,
16 and to comply with the corresponding disclosure requirements of Rule 26(a)(2) of the
17 Federal Rules of Civil Procedure by those dates. (Id. ¶¶ 3–5.) Like the first scheduling
18 order, the amended scheduling order specified further that any party that failed to make
19 the required disclosures would not, absent substantial justification, be permitted to use
20 the undisclosed evidence or testimony at any hearing or at trial, and could be subject to
21 sanctions under Rule 37. (Id. ¶¶ 4, 6.) The order also specified that any motion for
22 class certification had to be filed so as to be heard by April 25, 2016, and all other
23 pretrial motions had to be filed so as to be heard by August 29, 2016. (Id. ¶¶ 7–8.) As
24 a result, Plaintiff had until March 28, 2016, to move for class certification, and the
25 parties had until August 1, 2016, to file all other pretrial motions. See Civ. L.R.
26 7.1(e)(1).

27 ///

28 ///

1 On March 11, 2016, Plaintiff filed an ex parte motion to extend the deadline
2 to move for class certification. (Doc. No. 30.) Plaintiff did not indicate that he needed
3 more time to designate his experts. (See id.) On March 22, 2016, the magistrate judge
4 extended the deadline for Plaintiff to move for class certification. (Doc. No. 36.) She
5 concluded that Plaintiff had not shown good cause for an extension but permitted a
6 short extension, until April 11, 2016. (Id. at 3–6.)

7 On April 11, 2016, Plaintiff moved for certification of a nationwide class under
8 California law challenging claims on the product label and the product website, for a
9 period spanning more than a decade. (Doc. No. 39 at 12–13.) Defendant responded on
10 May 2, 2016. (Doc. No. 45.) On May 4, 2016, Plaintiff filed an ex parte motion
11 to continue the deadline to file a reply. (Doc. No. 46.) In requesting the extension,
12 he did not indicate a need for more time to designate his experts. (See id.) On May 4,
13 2016, the Court granted the extension and continued the motion hearing. (Doc. No. 47.)
14 On May 23, 2016, Plaintiff filed his reply in support of his motion for class
15 certification. (Doc. No. 50.)

16 Two days later, on May 25, 2016, Plaintiff filed an ex parte motion to continue
17 the deadline to designate expert witnesses. (Doc. No. 51.) Plaintiff noted that he had
18 retained two experts: a scientist who would address the IntenseX efficacy claims, and a
19 certified public accountant who would address damages. (Id. ¶ 2.) Plaintiff represented
20 that he needed more time because he had not yet received all of the documents he
21 needed for the expert damages report. (Id. ¶ 3.) Defendant opposed the motion. (Doc.
22 No. 52.) The magistrate judge denied the motion that afternoon, as Plaintiff had not
23 shown good cause for an extension. (Doc. No. 53.) On June 2, 2016, Plaintiff
24 submitted a supplemental declaration in support of his motion for class certification.
25 (Doc. No. 54 ¶¶ 2–3.)

26 On June 6, 2016, the Court held a hearing on the motion for class certification.
27 (Doc. No. 55.) On June 10, 2016, the Court denied certification. (Doc. No. 56.)
28 Among other difficulties, a classwide inference of reliance was not appropriate under

1 In re Tobacco II Cases, 46 Cal. 4th 298 (2009), because consumers were not exposed
2 to a widespread, long-term common marketing campaign. (Id. at 8.) Additionally,
3 Plaintiff did not submit sufficient evidence that the challenged representations were
4 material to consumers, that any significant portion of consumers shared Plaintiff's
5 understanding of the effects IntenseX would have, or that others similarly found the
6 product lacking. (Id.) As for Plaintiff's theory that IntenseX is a mislabeled
7 aphrodisiac, he had not shown that the regulation he relied on, which facially applies
8 only to over-the-counter drugs, applied to a supplement like IntenseX. (Id. at 9.)
9 Additionally, the Court noted choice-of-law problems with the proposed nationwide
10 class, as well as difficulties with standing, the statutes of limitations, calculating the
11 correct monetary remedy, and identifying class members. (Id. at 5–6, 9 n.3, 10–14.)

12 On July 29, 2016, Plaintiff filed his present motion for leave to file a renewed
13 motion for class certification, a renewed motion for class certification, and a motion to
14 exclude the report of Defendant's expert. (Doc. Nos. 58, 59, 62.) On August 1, 2016,
15 Defendant moved for summary judgment. (Doc. No. 63.)

16 On August 3, 2016, Defendant filed an ex parte motion to strike Plaintiff's
17 renewed motion for class certification or, alternatively, to stay the briefing schedule.
18 (Doc. No. 67.) The Court declined to stay the briefing schedule and set Defendant's ex
19 parte motion for hearing with the other motions. (Doc. No. 68.) In addition, the Court
20 directed the parties to address the merits of Plaintiff's renewed motion for class
21 certification as well as any timeliness issues, and also whether Plaintiff's experts are
22 true rebuttal experts and satisfy the requirements under Daubert v. Merrell Dow
23 Pharmaceuticals, Inc., 509 U.S. 579 (1993). (Id.)

24 On August 15, 2016, Plaintiff responded to Defendant's motion for summary
25 judgment and motion to strike Plaintiff's renewed motion for class certification (Doc.
26 No. 70, 74), and Defendant responded to Plaintiff's motions and filed moved to exclude
27 Plaintiff's rebuttal experts and for sanctions (Doc. Nos. 69, 71, 72, 73). On August 22,
28 2016, Plaintiff replied to Defendant's oppositions (Doc. Nos. 77, 78, 79), and

1 Defendant replied to Plaintiff's oppositions (Doc. Nos. 75, 76). On August 24, 2016,
 2 Plaintiff responded to Defendant's motion to exclude Plaintiff's rebuttal experts and for
 3 sanctions. (Doc. Nos. 80, 81.)

4 On August 25, 2016, the Court submitted all motions other than the motion for
 5 summary judgment under Civil Local Rule 7.1(d)(1). (Doc. No. 82.) On August 29,
 6 2016, the Court held a hearing on the motion for summary judgment. (Doc. No. 83.)
 7 William Richards appeared for Plaintiff. (Id.) Patty Lee appeared for Defendant. (Id.)

8 DISCUSSION

9 A. Class Certification

10 Plaintiff requests leave to file a renewed motion for class certification and, for the
 11 second time, moves for class certification. (Doc. Nos. 58, 59.) He proposes certifying
 12 a narrower class than the one he proposed the first time he moved for class certification:

13
 14 All persons in California who purchased IntenseX manufactured and/or
 15 distributed by PharmaCare US, Inc. for personal, family, or household use,
 16 and not for resale, since January 20, 2011, but excluding officers,
 17 directors, or employees of Defendant, individuals who have received a
 refund of their purchase of IntenseX, and purchasers of IntenseX from
 Defendant's websites.

18 (Doc. No. 59 at 14.) Plaintiff argues that this narrowed definition and other evidence
 19 cure the defects the Court identified in his original motion. (Doc. No. 58.)

20 Exercising its discretion, under the circumstances of this case the Court declines
 21 to permit Plaintiff to move for class certification a second time. As an initial matter,
 22 Plaintiff's motion is untimely under the case management scheduling orders. The
 23 amended scheduling order required Plaintiff to file his motion for class certification
 24 by March 28, 2016. (Doc. No. 27 ¶ 7); Civ. L.R. 7.1(e)(1). The Court extended the
 25 deadline for Plaintiff to move for class certification until April 11, 2016, not for good
 26 cause but because Defendant had not timely responded to some of Plaintiff's recovery
 27 requests. (Doc. No. 36.) Plaintiff filed his renewed motion for class certification on
 28 July 29, 2016, more than three months past the extended deadline. (Doc. No. 59.)

1 “A schedule may be modified only for good cause and with the judge’s consent.”
2 Fed. R. Civ. P. 16(b)(4).

3 Rule 16(b)’s “good cause” standard primarily considers the diligence of
4 the party seeking the amendment. The district court may modify the
5 pretrial schedule if it cannot reasonably be met despite the diligence of the
6 party seeking the extension. Moreover, carelessness is not compatible
7 with a finding of diligence and offers no reason for a grant of relief.
Although the existence or degree of prejudice to the party opposing
the modification might supply additional reasons to deny a motion, the
focus of the inquiry is upon the moving party’s reasons for seeking
modification. If that party was not diligent, the inquiry should end.

8 Johnson v. Mammoth Recreations, Inc., 975 F.2d 604, 609 (9th Cir. 1992) (citations
9 and internal quotation marks omitted). When the time to act has passed, on motion by a
10 party, a court may extend time “if the party failed to act because of excusable neglect.”
11 Fed. R. Civ. P. 6(b)(1)(B).

12 Plaintiff’s motion does not seek relief from the scheduling order and he has not
13 shown good cause or diligence to extend the deadline to move for class certification.
14 (See Doc. No. 58.) The Court notes that Plaintiff requested extensions of the deadlines
15 for class certification and expert disclosures but never mentioned the evidence he now
16 seeks to present. (See Doc. Nos. 30, 46, 51.)

17 Additionally, Plaintiff has not shown a sufficient basis for reconsideration
18 of the order denying his previous motion for class certification. Plaintiff notes that Rule
19 23(c)(1)(C) of the Federal Rules of Civil Procedures provides: “An order that grants
20 or denies class certification may be altered or amended before final judgment.”
21 (Doc. No. 58 at 3.)

22 After denying an initial motion for certification, however, courts are reluctant to
23 allow parties a second run at certification absent a significant, unexpected change in
24 circumstances to justify reconsideration of the original decision. See Newberg on Class
25 Actions §§ 7:34–7:35 (5th ed.); Hartman v. United Bank Card, Inc., 291 F.R.D. 591,
26 597 (W.D. Wash. 2013); Gustafson v. BAC Home Loans Servicing, LP, 2014 WL
27 10988335, at *2 (C.D. Cal. Feb. 5, 2014). This approach avoids relitigation of issues
28 that have already been litigated, “thereby incentivizing parties to put their best foot

1 forward at the outset and avoiding costly delays to the proceedings.” Newberg on Class
2 Actions § 7:35.

3 Reconsideration is generally appropriate only if there has been an intervening
4 change in controlling law, clear error, or new evidence has become available. See
5 389 Orange St. Partners v. Arnold, 179 F.3d 656, 665 (9th Cir. 1999). The plaintiff
6 “must show some justification for filing a second motion, and not simply a desire to
7 have a second or third run at the same issues.” Hartman, 291 F.R.D. at 597; Gustafson,
8 2014 WL 10988335, at *2.

9 Reconsideration is not warranted here. The Court relied on well established rules
10 regarding class certification when it denied the first motion. (See Doc. No. 56.)
11 Plaintiff could have presented the narrowed definition in his first motion but chose
12 not to. Moreover, he has not explained his failure to present his additional evidence
13 with his first motion. Accordingly, exercising its discretion, the Court declines to
14 permit Plaintiff a second run at class certification.

15 Additionally, even if the Court were to rule on Plaintiff’s renewed motion,
16 Plaintiff has not cured the central defects in his previous motion. (See Doc. No. 56.)
17 Plaintiff offers an FDA enforcement letter involving a different product. (Doc. No. 59
18 at 12 & Doc. No. 59-1, Exhs. 1–3.) But Plaintiff has not shown that the enforcement
19 letter applies to the IntenseX label.¹ (Doc. No. 59-1 Exh. 1 at 3.) Plaintiff’s purported
20 rebuttal expert on materiality and the perception of the reasonable consumer is not
21 being used for rebuttal. (See Doc. No. 59.) And, in any event, his opinion is not proper
22 expert opinion. (See Doc. No. 59-1, Exh. 6); Daubert v Merrell Dow Pharmaceuticals,
23 Inc., 509 U.S. 579 (1993). Accordingly, the Court denies Plaintiff’s motion for leave
24

25 ¹ Plaintiff testified at his deposition that he bought IntenseX in stores on two
26 occasions and, although he saw the website between purchases, it had “no effect” on his
27 decision to buy IntenseX again. (Doc. No. 63-4 at 56:16–58:4; Doc. No. 63-5 at
28 8:9–9:18, 14:13–15:19.) Defendant submitted the declaration of its marketing manager
stating that the product website never contained any customer reviews. (Doc. No. 63-9
¶ 4). Additionally, Plaintiff’s narrowed proposed class excludes website purchasers.
(Doc. No. 59 at 14.)

1 to file a renewed motion for class certification, and denies his renewed motion for class
2 certification.² (Doc. Nos. 58, 59.)

3 **B. Motion for Summary Judgment**

4 Summary judgment is appropriate under Rule 56 of the Federal Rules of Civil
5 Procedure if the moving party demonstrates that there is no genuine issue of material
6 fact and that it is entitled to judgment as a matter of law. See Celotex Corp. v. Catrett,
7 477 U.S. 317, 322 (1986). A fact is material if it could affect the outcome of the case
8 under the governing substantive law. See Anderson v. Liberty Lobby, Inc., 477 U.S.
9 242, 248 (1986). “Disputes over irrelevant or unnecessary facts will not preclude a
10 grant of summary judgment.” T.W. Elec. Serv., Inc. v. Pac. Elec. Contractors Ass’n,
11 809 F.2d 626, 630 (9th Cir. 1987).

12 The party moving for summary judgment bears the initial burden of establishing
13 the absence of a genuine issue of material fact. See Celotex, 477 U.S. at 323. There are
14 two ways to satisfy this burden: (1) presenting evidence that negates an essential
15 element of the nonmoving party’s case; or (2) demonstrating that the nonmoving party
16 failed to establish an essential element that the nonmoving party bears the burden of
17 proving at trial. See id. at 322–23. Once the moving party establishes the absence of
18 a genuine issue of material fact, the burden shifts to the nonmoving party to “set forth,
19 by affidavit or as otherwise provided in Rule 56, specific facts showing that there
20 is a genuine issue for trial.” T.W. Elec. Serv., 809 F.2d at 630 (internal quotation
21 marks omitted). To carry its burden, the non-moving party “may not rest upon mere
22 allegations or denials of his pleadings.” Anderson, 477 U.S. at 256. Rather, the non-
23 moving party “must present affirmative evidence . . . from which a jury might return a
24 verdict in his favor.” Id.

25 ///

26
27 ² Plaintiff has not shown good cause to vary from the case management
28 scheduling order, but the Court denies as moot Defendant’s motion to strike Plaintiff’s
renewed motion for class certification. (Doc. No. 67.)

1 **1. UCL, FAL, and CLRA Claims**

2 Plaintiff asserts claims under the UCL, FAL, and CLRA. (FAC ¶¶ 99–125.)
 3 Defendant contends that it is entitled to summary judgment on these claims because
 4 Plaintiff cannot challenge the statements on the IntenseX website, the statements on the
 5 IntenseX label are not actionable, and Plaintiff is not entitled to the remedies he prays
 6 for in his first amended complaint. (Doc. No. 63-1 at 11–16.) Plaintiff opposes. (Doc.
 7 No. 70 at 11–26.)

8 Regarding the statements on the IntenseX website, Defendant points out that
 9 “actual reliance” is a necessary element of a fraud claim under the UCL, FAL, and
 10 CLRA. See Kwikset Corp. v. Superior Court, 51 Cal. 4th 310, 326 (2011); In re
 11 Tobacco II Cases, 46 Cal. 4th 298, 326 (2009); Sevidal v. Target Corp., 189 Cal. App.
 12 4th 905, 928 (2010). Plaintiff testified at his deposition that he bought IntenseX in
 13 stores on two occasions and, although he saw the website between purchases, it had “no
 14 effect” on his decision to buy IntenseX again. (Doc. No. 63-4 at 56:16–58:4; Doc. No.
 15 63-5 at 8:9–9:18, 14:13–15:19.) Moreover, Plaintiff testified that he only looked at the
 16 reviews on the website. (Doc. No. 65-3 at 14:13–14:25.) Defendant submitted the
 17 declaration of its marketing manager stating that the product website never contained
 18 any customer reviews. (Doc. No. 63-9 ¶ 4). As a result, Plaintiff cannot premise his
 19 fraud claims on the statements on the product website.

20 Plaintiff argues that he does not need to show reliance for his “unlawful” claims
 21 because “illegality is considered material.” (Doc. No. 70 at 16.) But his authority
 22 does not stand for such a broad rule. See In re Steroid Hormone Prod. Cases, 181 Cal.
 23 App. 4th 145, 157 (2010) (holding that reasonable person would find it material that the
 24 product was “unlawful to sell or possess”). Moreover, Plaintiff’s “unlawful” claims are
 25 premised on fraud, hence subject to the “actual reliance” requirement like any other
 26 fraud claim. See Kwikset Corp., 51 Cal. 4th at 326 n.9. Accordingly, the Court grants
 27 judgment for Defendant on Plaintiff’s theories related to the claims on the IntenseX
 28 website.

1 As for Plaintiff's claims that the IntenseX label is false and misleading,
2 Defendant argues that the statements on the label are too generalized and vague to be
3 actionable. (Doc. No. 63-1 at 12–13.) Claims of false or misleading advertising are
4 governed by the “reasonable consumer” test. Williams v. Gerber Prods. Co., 552 F.3d
5 934, 938 (9th Cir.2008). To satisfy the test, a plaintiff must show that “members
6 of the public are likely to be deceived.” Freeman v. Time, Inc., 68 F.3d 285, 289
7 (9th Cir.1995). “Likely to be deceived” means that “it is probable that a significant
8 portion of the general consuming public or of targeted consumers, acting reasonably in
9 the circumstances, could be misled.” Lavie v. Procter & Gamble Co., 105 Cal. App. 4th
10 496, 508 (2003). “[I]f the alleged misrepresentation, in context, is such that no
11 reasonable consumer could be misled, then the allegation may . . . be dismissed as a
12 matter of law.” Haskell v. Time, Inc., 857 F. Supp. 1392, 1399 (E.D. Cal. 1994).

13 Moreover, Plaintiff has a claim for false advertising only to the extent the product
14 claims are false or misleading, as opposed to merely unsubstantiated. See In re Clorox
15 Consumer Litig., 894 F. Supp. 2d 1224, 1232 (N.D. Cal. 2012) (“Consumer claims for a
16 lack of substantiation are not cognizable under California law.”); Nat’l Council Against
17 Health Fraud, Inc. v. King Bio Pharm., Inc., 107 Cal. App. 4th 1336, 1345 (2003)
18 (“Private plaintiffs are not authorized to demand substantiation for advertising
19 claims.”). The plaintiff can carry his burden of showing that claims are false with
20 studies showing that a statement is false. See Bronson v. Johnson & Johnson, Inc.,
21 2013 WL 1629191, at *8 (N.D. Cal. Apr. 16, 2013). However, “reliance on a lack of
22 scientific evidence or inconclusive, rather than contradictory, evidence is not
23 sufficient.” Id.

24 The IntenseX label bears the IntenseX logo and statements including “Sexual
25 Power & Performance,” “Fast Acting!” and “designed to intensify your endurance,
26 stamina, and sexual performance.” (Doc. No. 71-1, Exh. 1.) As Plaintiff's own expert
27 points out, however, “the vague language used with respect to IntenseX effects on
28 sexuality (‘sexual power and performance’) has no support as such terms remain

1 scientifically undefined and therefore untestable.” (Doc. No. 70-1, Exh. 4 ¶ 26.) The
2 Court agrees that the statements on the IntenseX label are too vague, general, and
3 subjective to be actionable.

4 Next, Defendant argues that it is entitled to summary judgment on Plaintiff’s
5 claim that IntenseX is unlawful because its label makes impermissible “disease” claims.
6 (Doc. No. 63-1 at 12.) In the September 30, 2015 order on Defendant’s motion to
7 dismiss and strike Plaintiff’s first amended complaint, the Court concluded that
8 the Food, Drug, and Cosmetic Act preempts Plaintiff’s theory that the IntenseX
9 label makes impermissible “disease” claims. (Doc. No. 17 at 6–8.) Accordingly,
10 the Court grants judgment for Defendant on this claim.

11 Similarly, in the order on Plaintiff’s first motion for class certification, the Court
12 noted that the regulation Plaintiff relies on to contend that IntenseX is a mislabeled
13 aphrodisiac drug, 21 C.F.R. § 310.528 facially applies only to over-the-counter drugs,
14 and that over-the-counter drugs and supplements are subject to different regulatory
15 schemes. (Doc. No. 56 at 9.) Plaintiff contends that an FDA enforcement letter for
16 another product shows that the FDA applies the regulation to supplements. (Doc. No.
17 59 at 12–13, 23.)³ But Plaintiff has not shown that the regulation applies to IntenseX.
18 Accordingly, the Court grants summary judgment for Defendant on Plaintiff’s claims
19 under the UCL, FAL, and CLRA.

20 **2. State-Law Warranty Claims**

21 Plaintiff asserts claims under state law for breach of express warranty and
22 breach of the implied warranty of merchantability. (FAC ¶¶ 126–36.) Defendant points
23 out, correctly, that Plaintiff cannot rest his express warranty claim on the statements on
24 the IntenseX website. (Doc. No. 63-1 at 18.) Plaintiff testified at his deposition that he
25 did not buy IntenseX from Defendant and did not rely on the statements on the IntenseX
26

27 ³ The parties addressed this theory in their briefing on the motions related
28 to Plaintiff’s renewed motion for class certification. The Court notes that Defendant
moves for summary judgment on all of Plaintiff’s claims. (Doc. No. 63 at 3.)

1 website when making his purchases. (Doc. No. 63-5 at 8:9–9:18, 14:13–15:19.)
 2 “[I]n the absence of privity, California law requires a showing that a plaintiff relied on
 3 an alleged omission or misrepresentation.” Keegan v. Am. Honda Motor Co., 284
 4 F.R.D. 504, 546 (C.D. Cal. 2012).

5 As for warranties created by the IntenseX label, Defendant argues that Plaintiff
 6 cannot establish that the label created a warranty and that Plaintiff did not reasonably
 7 rely on the statements that purportedly created a warranty. (Doc. No. 63-1 at 17–19.)

8 Any affirmation of fact or promise relating to a product or any description of
 9 the product that becomes part of the basis of the bargain creates an express warranty
 10 that the product will conform to the affirmation, promise, or description. See Hauter
 11 v. Zogarts, 14 Cal. 3d 104, 115 n.9 (1975). An express warranty claim requires the
 12 plaintiff to prove a warranty has been breached. See Scott v. Metabolife Int’l, Inc.,
 13 115 Cal. App. 4th 404, 415–16 (2004). Similarly, a plaintiff who claims a breach of the
 14 implied warranty of merchantability must show that the product did not “conform to the
 15 promises or affirmations of fact made on the container or label,” or was not “fit for the
 16 ordinary use for which such goods are used.” Hauter, 14 Cal. 3d at 117–18.

17 These claims, like Plaintiff’s UCL, FAL, and CLRA claims, rely on the theory
 18 that the label made promises that were not true. They fall short for the same reasons.
 19 Accordingly, the Court grants judgment for Defendant on Plaintiff’s warranty claims.

20 **3. Magnuson-Moss Warranty Act Claim**

21 Last, Plaintiff asserts a claim under the federal Magnuson-Moss Warranty Act.
 22 (FAC ¶¶ 137–46.) As Defendant points out, however, the Magnuson-Moss Warranty
 23 Act has a jurisdictional minimum that Plaintiff’s claim does not satisfy:

24 No claim shall be cognizable in a suit brought under paragraph (1)(B) of
 25 this subsection—

26 (A) if the amount in controversy of any individual claim is less than the
 sum or value of \$25;

27 (B) if the amount in controversy is less than the sum or value of \$50,000
 28 (exclusive of interests and costs) computed on the basis of all claims to be
 determined in this suit; or

(C) if the action is brought as a class action, and the number of named plaintiffs is less than one hundred.

15 U.S.C. § 2310(d)(3).

This case is no longer a putative class action, and Plaintiff said at his deposition that he bought IntenseX for \$9.99 twice. (Doc. No. 63-4 at 42:16–42:17; Doc. No. 63-5 at 25:14–25:19.) As a result, this Court lacks jurisdiction over Plaintiff’s Magnuson-Moss warranty claim and dismisses it on that basis.⁴

C. Motion to Exclude Plaintiff’s Rebuttal Experts and For Sanctions

Defendant moves to exclude Plaintiff’s experts because they are not proper rebuttal experts and asks the Court to sanction Plaintiff by excluding the improper rebuttal opinions and ordering Plaintiff to pay the legal expenses Defendant incurred in moving to exclude Plaintiff’s experts and in opposing Plaintiff’s renewed motion for class certification. (Doc. No. 71.)

Exercising its discretion, the Court declines to issue sanctions and construes the filings on the motion as supplemental briefing on the other pending motions. The Court requested briefing on whether Plaintiff’s rebuttal experts satisfy the requirements of Daubert v Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), and whether any part of Plaintiff’s “rebuttal” reports are rebuttal within the meaning of Federal Rule of Civil Procedure 26(a)(2)(D)(ii). (Doc. No. 68 at 2.) The Court did not invite a motion for sanctions. Additionally, Defendant’s motion did not comply with Civil Local Rules 7.1(b) and (e)(1).

However, the scheduling orders plainly specified that any party that failed to make the required disclosures would not, absent substantial justification, be permitted to use the undisclosed evidence or testimony at any hearing or at trial. (Doc. No. 26 ¶¶ 4, 6; Doc. No. 27 ¶¶ 4, 6.) Plaintiff did not disclose Dr. Belch, his consumer expert, by

⁴ The Court denies as moot Plaintiff’s motion to exclude the report of Defendant’s expert. (Doc. No. 62.) Defendant did not use the report to support its motion for summary judgment, which the Court has granted.

1 the May 27, 2016 deadline for disclosing affirmative experts. (Doc. No. 71 at 10; Doc.
 2 No. 71-1 ¶¶ 2–7.) Plaintiff concedes that he is attempting to use the purported rebuttal
 3 for purposes other than rebuttal. (Doc. No. 80 at 5.) And, while Plaintiff did disclose
 4 his other expert, Dr. Rowland, by the May 27, 2016 deadline (Doc. No. 71-1 ¶ 2),
 5 Plaintiff relies on the purported rebuttal to carry his positive burdens at class
 6 certification and summary judgment. Plaintiff cannot cure the untimeliness of his
 7 disclosures by deeming the reports rebuttal when they are not.


8 “Decisions concerning the use of rebuttal evidence lie within the sound discretion
 9 of the trial court.” United States v. Pheaster, 544 F.2d 353, 383 (9th Cir. 1976.)
 10 Exercising its discretion, and pursuant to the scheduling order, the Court permits
 11 Plaintiff to use his rebuttal reports only to the extent they are true rebuttal.

12 CONCLUSION

13 For the foregoing reasons, the Court denies Plaintiff’s motions regarding class
 14 certification (Doc. Nos. 58, 59), and grants Defendant’s motion for summary judgment
 15 as to all claims other than the Magnuson-Moss Warranty Act claim, which the Court
 16 dismisses for lack of jurisdiction (Doc. No. 63). Additionally, the Court denies
 17 Defendant’s motion for sanctions and to exclude Plaintiff’s rebuttal experts, but limits
 18 Plaintiff to using his rebuttal experts for rebuttal. (Doc. No. 71.) The Court denies as
 19 moot Defendant’s motion to strike Plaintiff’s renewed motion for class certification
 20 (Doc. No. 67) and denies as moot Plaintiff’s motion to exclude the report of
 21 Defendant’s expert (Doc. No. 62).

22 IT IS SO ORDERED.

23 DATED: August 29, 2016

24 
 25 MARILYN L. HUFF, District Judge
 26 UNITED STATES DISTRICT COURT
 27
 28